Antrodia salmonea

Antrodia salmonea fruiting bodies are rich in ergostane- and lanostane-type triterpenoids—most abundantly (R,S)-antcin C at 184.85 µg/mg dry extract—which drive anti-inflammatory, antioxidant, and cytotoxic activities through modulation of oxidative stress pathways and ACE2 surface expression. In vitro, its polyphenol extract achieves DPPH radical scavenging of 94.10%, ABTS scavenging of 83.34%, and hydroxyl radical scavenging of 95.42% at 0.1 mg/mL, while antcin-class compounds reduce ACE2 levels in HT-29 cells from 11.23 ng/mL to 4.39 ng/mL.

Origin & History

Antrodia salmonea is a wood-rotting polypore fungus native to Taiwan, closely related to the endemic and highly prized Antrodia cinnamomea. Like its congeners, it grows on the heartwood of specific host trees in Taiwan's montane forests, though its precise host specificity and geographic range are less thoroughly documented than A. cinnamomea. The fungus produces salmon-colored fruiting bodies and has attracted scientific interest due to its distinct triterpenoid and volatile chemical profiles that differ meaningfully from related Antrodia species.

Historical & Cultural Context

Antrodia salmonea does not have an independently documented history of traditional use in Taiwanese or other indigenous medicine; the cultural and historical context relevant to this species is largely derived from its close taxonomic relationship with Antrodia cinnamomea, which is endemic to Taiwan and has been used for centuries by indigenous Taiwanese communities as 'Niu Chang Chih' or 'Zhang Zhi.' In Taiwanese folk medicine, Antrodia cinnamomea and related Antrodia species have been administered as decoctions or tinctures for liver protection, detoxification, anti-fatigue, and anti-tumor purposes, with the fruiting bodies historically harvested from the inner heartwood of the endemic camphor tree Cinnamomum kanehirae. Antrodia salmonea likely shares overlapping ecological niches with A. cinnamomea in Taiwan's forest ecosystems, and its distinct salmon-colored fruiting body morphology distinguishes it visually, though ethnobotanical records documenting specific intentional harvesting or use of A. salmonea as a distinct species are absent from the current literature. Scientific characterization of A. salmonea as a chemically distinct species represents a relatively recent development driven by comparative metabolomics research rather than longstanding traditional application.

Health Benefits

- **Antioxidant Protection**: Polyphenol-rich fruiting body extracts scavenge DPPH radicals at 94.10%, ABTS radicals at 83.34%, and hydroxyl radicals at 95.42% at 0.1 mg/mL, suggesting potent free-radical neutralization capacity relevant to oxidative stress-related conditions.
- **Anti-Inflammatory Activity**: Fruiting body extracts demonstrate stronger suppression of inflammation markers than Antrodia cinnamomea extracts in comparative in vitro assays, likely attributable to the high concentrations of antcin-class triterpenoids that modulate pro-inflammatory signaling cascades.
- **Liver Protection (Hepatoprotective Potential)**: Antcin A and antcin C—present at 57.85 µg/mg and 184.85 µg/mg respectively—are structurally analogous to steroids with documented hepatoprotective properties in related Antrodia species, supporting traditional use of Antrodia fungi for liver health.
- **Cytotoxic Activity Against Cancer Cells**: Fruiting body extracts exhibit cytotoxicity against MCF-7 human breast cancer cells with an IC50 of 91.45 µg/mL in vitro, indicating selective antiproliferative effects that merit further mechanistic and preclinical investigation.
- **ACE2 Surface Expression Reduction**: Antcin-class compounds derived from Antrodia salmonea and related species significantly reduce ACE2 protein levels in HT-29 colorectal cells from 11.23 ng/mL to 4.39 ng/mL, a mechanism theorized to limit SARS-CoV-2 cellular entry points.
- **Antibacterial Activity**: Fractionated extracts demonstrate antibacterial activity against resistant bacterial strains with minimum inhibitory concentrations (MICs) ranging from 64 to 256 µg/mL, suggesting bioactive compounds capable of disrupting bacterial cell integrity.
- **Unique Triterpenoid Diversity**: Antrodia salmonea produces species-specific compounds antcin M and methyl antcinate K absent in A. cinnamomea, expanding the known pharmacological repertoire of the Antrodia genus and providing a chemotaxonomic signature with potential undiscovered bioactivities.

How It Works

The dominant triterpenoids in Antrodia salmonea—particularly (R,S)-antcin C (184.85 µg/mg), antcin A (57.85 µg/mg), antcin H (19.86 µg/mg), and antcin K (18.61 µg/mg)—are ergostane- and lanostane-skeleton steroids that interact with nuclear receptors and transcription factors governing oxidative stress and inflammatory gene expression, analogous to mechanisms characterized for antcins in A. cinnamomea. The antcin compounds downregulate ACE2 receptor expression at the cell surface in HT-29 intestinal epithelial cells, reducing available docking sites for SARS-CoV-2 spike protein and potentially limiting viral cell entry. Polyphenolic constituents donate electrons or hydrogen atoms to neutralize reactive oxygen species including DPPH, ABTS cation radicals, and hydroxyl radicals, protecting cellular macromolecules from oxidative damage through non-enzymatic antioxidant mechanisms. The sesquiterpene volatiles α-cedrene (14.68%), germacrene D (7.22%), and α-muurolene (5.31%) contribute to the anti-inflammatory and antibacterial activities through membrane-disrupting and receptor-modulating mechanisms documented for this terpene class in other fungal contexts.

Scientific Research

The available body of evidence for Antrodia salmonea consists exclusively of in vitro laboratory studies, with no published human clinical trials, animal model studies, or pharmacokinetic data identified as of the current literature review. Comparative phytochemical studies have quantified triterpenoid profiles by HPLC and volatile compositions by GC-MS, establishing (R,S)-antcin C as the dominant compound at 184.85 µg/mg, and demonstrating species-specific markers antcin M and methyl antcinate K absent in the related A. cinnamomea. Cytotoxicity against MCF-7 breast cancer cells (IC50 = 91.45 µg/mL) and ACE2 downregulation in HT-29 cells represent the most quantitatively characterized bioactivities, though these cell-line findings cannot be extrapolated to human therapeutic outcomes without further preclinical and clinical investigation. The evidence base is currently at a preliminary, hypothesis-generating stage, and the pharmacological properties of A. salmonea in living systems remain largely uncharacterized.

Clinical Summary

No clinical trials have been conducted specifically on Antrodia salmonea in human subjects, and no animal model pharmacology studies are currently reported in the accessible literature. The closest translational context comes from clinical investigations of the related species Antrodia cinnamomea (e.g., LEAC-102 extract studies for fatigue and liver markers), but these findings cannot be directly applied to A. salmonea given the distinct triterpenoid profiles, including species-specific compounds antcin M and methyl antcinate K. All quantified outcomes—including antioxidant scavenging rates, ACE2 reduction, cytotoxic IC50 values, and antibacterial MICs—derive from cell-culture assays at concentrations that may not reflect achievable human plasma levels. Confidence in clinical benefit is therefore very low, and regulatory bodies would require substantial additional preclinical and clinical research before any therapeutic or health claims could be substantiated.

Nutritional Profile

The nutritional macrocomposition of Antrodia salmonea fruiting bodies has not been comprehensively analyzed in published literature; however, as a wood-decaying polypore fungus, it is expected to contain structural polysaccharides (beta-glucans, chitin), proteins, and minimal lipids consistent with other medicinal fungi. The most thoroughly characterized constituents are triterpenoids: (R,S)-antcin C at 184.85 ± 0.96 µg/mg dry extract, (R,S)-antcin A at 57.85 ± 0.11 µg/mg, (R,S)-antcin H at 19.86 ± 0.28 µg/mg, and (R,S)-antcin K at 18.61 ± 0.33 µg/mg, along with species-unique antcin M and methyl antcinate K. Volatile terpenoids constitute a significant fraction of the chemical identity, dominated by α-cedrene (14.68%), 1-octen-3-ol (9.31%), D-limonene (9.21%), cadinadiene (7.65%), germacrene D (7.22%), isolongifolene (6.72%), and α-muurolene (5.31%). Bioavailability of the triterpenoids in humans is unknown, as no pharmacokinetic studies have been conducted; lipophilic triterpenoids in other fungal species generally show moderate oral bioavailability enhanced by co-administration with dietary fat.

Preparation & Dosage

- **Fruiting Body Dry Extract (Research Use)**: Concentrations of 0.1 mg/mL used in in vitro antioxidant assays; no human-equivalent dose established.
- **Ethanol/Methanol Fruiting Body Extract**: Used in cytotoxicity and anti-inflammatory studies at concentrations yielding IC50 = 91.45 µg/mL against MCF-7 cells; no clinical dose translation available.
- **Triterpenoid-Standardized Extract (Proposed)**: Given that antcin C dominates at 184.85 µg/mg dry extract, standardization to antcin C content is scientifically rational but no commercial standard or validated assay threshold exists for A. salmonea specifically.
- **Traditional Decoction (Antrodia genus)**: Related Antrodia species are traditionally prepared as hot-water decoctions of dried fruiting bodies in Taiwanese folk medicine, typically 3–9 g dried material per day, but this method and dose have not been validated for A. salmonea.
- **No Established Supplemental Form**: No capsule, tablet, tincture, or standardized supplement form has been commercially developed or clinically evaluated for Antrodia salmonea as of current literature; any commercial product should be approached with caution due to the absence of dosing guidance.

Synergy & Pairings

In the context of related Antrodia species, triterpenoid-rich extracts have been theorized to demonstrate additive or synergistic antioxidant effects when combined with vitamin C or vitamin E, as these compounds operate through complementary radical-scavenging mechanisms—aqueous versus lipid-phase—that together provide broader oxidative stress coverage. Given the ACE2-downregulating activity of antcin-class compounds, combinatorial investigation with other anti-inflammatory botanicals such as quercetin or luteolin (which also modulate NF-κB and ACE2-related pathways) is scientifically plausible but entirely unstudied for A. salmonea specifically. The hepatoprotective triterpenoid profile of A. salmonea may theoretically complement milk thistle (silymarin) liver-support stacks, as silymarin acts through distinct mechanisms involving Nrf2 activation and bile acid regulation, but no experimental data support this combination for this species.

Safety & Interactions

No human safety data, adverse event reports, or toxicology studies have been published for Antrodia salmonea, making a definitive safety profile impossible to construct from current evidence. The cytotoxicity observed against MCF-7 breast cancer cells at IC50 = 91.45 µg/mL—which is higher (less potent) than the IC50 of A. cinnamomea at 59.18 µg/mL—suggests moderate cytotoxic potential that warrants caution regarding high-dose supplementation until in vivo toxicology data are available. No drug interaction studies exist; however, given that antcin-class triterpenoids in related Antrodia species have been associated with modulation of hepatic enzyme activity in preclinical contexts, theoretical interactions with CYP450-metabolized drugs (anticoagulants, immunosuppressants, antiepileptics) cannot be excluded. Use during pregnancy or lactation is not recommended due to complete absence of safety data; individuals with known liver disease, autoimmune conditions, or those taking prescription medications should consult a qualified healthcare provider before use.